FMS - Fresenius Medical Care announces company reorganization
Fresenius Medical Care (NYSE:FMS) has restructured its operating model with changes to the management board effective Jan. 01, 2022. German-based healthcare services provider focused on renal care has established two new units operating globally: Care Delivery segment and Care Enablement segment. Led by William Valle, Fresenius Medical’s (FMS) current CEO for North America, the Care Delivery segment will combine the global healthcare services business. Managed by Katarzyna Mazur-Hofsäß, the company’s current CEO for Europe, Middle East, and Africa (EMEA) region, the Care Enablement segment will house healthcare products business under a MedTech unit. While Rice Powell remains CEO of Fresenius Medical (FMS), Harry de Wit, CEO for Asia-Pacific, Kent Wanzek, CEO for Global Manufacturing, Quality and Supply (GMQS), Olaf Schermeier, CEO for R&D will join the company’s executive committee from its management board. Recently, Fresenius Medical (FMS) announced a strategic distribution partnership with JMS Co., covering the Japanese market.
For further details see:
Fresenius Medical Care announces company reorganization